Cargando…

Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo

Despite recent advances in treatment, the prognosis of oral cancer remains poor, and prevention of recurrence and metastasis is critical. Olaparib is a PARP1 inhibitor that blocks polyADP-ribosylation, which is involved in the epithelial–mesenchymal transition (EMT) characteristic of tumor recurrenc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Nanami, Fujihara, Hisako, Kawaguchi, Koji, Yamada, Hiroyuki, Nakayama, Ryoko, Yasukawa, Masaaki, Kishi, Yuta, Hamada, Yoshiki, Masutani, Mitsuko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909974/ https://www.ncbi.nlm.nih.gov/pubmed/35269669 http://dx.doi.org/10.3390/ijms23052527

Ejemplares similares

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo
por: Yasukawa, Masaaki, et al.
Publicado: (2016)

PARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling Pathway
por: Kishi, Yuta, et al.
Publicado: (2015)

Detection accuracy for epithelial dysplasia using an objective autofluorescence visualization method based on the luminance ratio
por: Yamamoto, Nanami, et al.
Publicado: (2017)

Spontaneous Development of Dental Dysplasia in Aged Parp-1 Knockout Mice
por: Fujihara, Hisako, et al.
Publicado: (2019)

XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA
por: Hirota, Kouji, et al.
Publicado: (2022)

Solitary myofibroma of the mandible in an adult with magnetic resonance imaging and positron emission tomography findings: a case report
por: Tanaka, Yoko, et al.
Publicado: (2014)

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
por: Nakamura, Kohei, et al.
Publicado: (2020)

Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma
por: Kawaguchi, Koji, et al.
Publicado: (2010)

Suppression of Gl Arrest and Enhancement of G2 Arrest by Inhibitors of Poly(ADP‐ribose) Polymerase: Possible Involvement of Poly(ADP‐ribosyl)ation in Cell Cycle Arrest Following γ‐Irradiation
por: Nozaki, Tadashige, et al.
Publicado: (1994)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Possible Role of the Polyglutamine Elongation in Evolution of Amyloid-Related Evolvability
por: Hashimoto, Makoto, et al.
Publicado: (2018)

Possible Role of Amyloid Cross-Seeding in Evolvability and Neurodegenerative Disease
por: Hashimoto, Makoto, et al.
Publicado: (2019)

Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study
por: Tashiro, Ryota, et al.
Publicado: (2022)

Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study
por: Tashiro, Ryota, et al.
Publicado: (2023)

The combination of olaparib and camptothecin for effective radiosensitization
por: Miura, Katsutoshi, et al.
Publicado: (2012)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma
por: Navran, Arash, et al.
Publicado: (2023)

ADP-Ribosylation as Post-Translational Modification of Proteins: Use of Inhibitors in Cancer Control
por: Poltronieri, Palmiro, et al.
Publicado: (2021)

Characterization of the relationship between neutron production and thermal load on a target material in an accelerator-based boron neutron capture therapy system employing a solid-state Li target
por: Nakamura, Satoshi, et al.
Publicado: (2019)

Editorial Comment on “Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin”
por: Hatano, Koji
Publicado: (2022)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Olaparib-Induced Immune-Mediated Liver Injury
por: Alshelleh, Mohammad, et al.
Publicado: (2022)

A case of hand-foot syndrome with olaparib
por: da Costa, Rafael Everton Assunção Ribeiro, et al.
Publicado: (2022)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
por: Kageyama, Shun-ichiro, et al.
Publicado: (2020)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
por: Wu, Min, et al.
Publicado: (2018)

Comparison of Adverse Reactions Caused by Olaparib for Different Indications
por: Zhou, Yujing, et al.
Publicado: (2022)

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
por: Clark, Abigale, et al.
Publicado: (2023)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Neutron flux evaluation model provided in the accelerator-based boron neutron capture therapy system employing a solid-state lithium target
por: Nakamura, Satoshi, et al.
Publicado: (2021)

Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation
por: Huang, Duen-Yi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c91gk24038sb1a5g3fn8nm07kd